Following these proceedings, H.C. Wainwright initiated its ImmunityBio Inc [IBRX] rating to a Buy in a research note published on March 06, 2025; the price target was $8. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Piper Sandler also remained covering IBRX and has decreased its forecast on May 12, 2023 with a “Neutral” recommendation from previously “an Overweight” rating. Jefferies started covering the stock on August 03, 2022. It rated IBRX as “a Buy”.
Price Performance Review of IBRX
On Monday, ImmunityBio Inc [NASDAQ:IBRX] saw its stock fall -17.32% to $2.10. Over the last five days, the stock has lost -20.15%. ImmunityBio Inc shares have fallen nearly -17.97% since the year began. Nevertheless, the stocks have fallen -75.41% over the past one year. While a 52-week high of $10.01 was reached on 02/19/25, a 52-week low of $2.28 was recorded on 05/05/25. SMA at 50 days reached $2.79, while 200 days put it at $3.65.
Levels Of Support And Resistance For IBRX Stock
The 24-hour chart illustrates a support level at 1.92, which if violated will result in even more drops to 1.75. On the upside, there is a resistance level at 2.35. A further resistance level may holdings at 2.60. The Relative Strength Index (RSI) on the 14-day chart is 33.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.29%. Stochastics %K at 16.16% indicates the stock is a buying.
How much short interest is there in ImmunityBio Inc?
A steep rise in short interest was recorded in ImmunityBio Inc stocks on 2025-04-15, growing by 7.64 million shares to a total of 67.18 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 59.54 million shares. There was a rise of 11.37%, which implies that there is a positive sentiment for the stock.
